ERBB2 and breast carcinoma: We compared the sensitivity of the NZBR cell lines and other breast cancer cell lines with or without ER or HER2 to the HER2 inhibitors lapatinib, afatinib, dacomitinib and ARRY-380 (ONT-380; irbinitinib; tuncatinib).